story of the week
Patient-Reported Outcomes of Capivasertib Plus Fulvestrant Therapy for HR+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Oncol 2024 Sep 01;25(9)1231-1244, M Oliveira, HS Rugo, SJ Howell, F Dalenc, J Cortes, HL Gomez, X Hu, M Toi, K Jhaveri, P Krivorotko, S Loibl, S Morales Murillo, M Okera, Z Nowecki, YH Park, JH Sohn, E Tokunaga, S Yousef, L Zhukova, M Fulford, H Andrews, I Wadsworth, C D'Cruz, NC TurnerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.